(All fields required)
Please enter a valid email.
Please enter your name.
The Kidney Tumor Program, part of the Cancer and Blood Diseases Institute, is home to specialists with a wide variety of backgrounds and areas of focus. As a team, this diversity makes us better prepared to care for your child’s unique needs.
Medical Director James Geller, MD, works closely with John J. Bissler, MD, a nephrologist at Cincinnati Children’s. Dr. Bissler was recently appointed to serve as the first committee nephrologist for the Children’s Oncology Group Renal Tumor Committee. This is the national committee for the development and implementation of clinical research trials for the treatment of pediatric kidney cancer. Dr. Bissler focuses on clinical and scientific research in neoplastic growth in the kidneys, with a specific focus on tuberous sclerosis and renal angiomyolipomas.
Learn more about our faculty, fellows and staff.
James I. Geller, MD Medical Director, Kidney and Liver Tumors Program
Medical Director, Kidney and Liver Tumors Program
Co-Medical Director, Retinoblastoma Program
Associate Director, Global Cancer Programs
Associate Professor, UC Department of Pediatrics
Developmental therapeutics; renal / liver / retinoblastoma / neuro-oncology
Elucidating ways to translate the use of biological response modifiers in combination with conventional chemotherapeutics
MD: Sackler School of Medicine, 1997.
Residency: New York Medical College, 2000.
Fellowship: St Jude Children's Research Hospital, 2004.
Certification: Pediatrics, 2000, 2007; Pediatric Hematology / Oncology, 2005.
Geller JI, Meyers AB, Towbin AJ, Serai S, Geller JI, Podberesky DJ. Characterization of pediatric liver lesions with gadoxetate disodium. Pediatr Radiol. 2011 Sep;41(9):1183-97.
Pressey JG, Wright JM, Geller JI, Joseph DB, Pressey CS, Kelly DR. Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex. Pediatr Blood Cancer. 2010 Jul 1;54(7):1035-7.
Cripe TP. Adenovirus gene therapy for pediatric cancers: shall we gather at the liver? Pediatr Blood Cancer. 2009 Aug;53(2):133-5.
Geller JI, Dome JS. Retroperitoneal lymph node dissection for pediatric renal cell carcinoma. Pediatr Blood Cancer. 2009 Mar;52(3):430.
Geller JI, Leslie ND, Yin H. Malignant Rhabdoid Tumor. eMedicine from WebMD. 2009 Dec. Available online.
Geller JI, Wall D, Perentesis J, Blaney SM, Bernstein M; Pediatric Oncology Group study 9376. Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376). Pediatr Blood Cancer. 2009 Mar;52(3):346-50.
Geller JI. Genetic stratification of Wilms tumor: is WT1 gene analysis ready for prime time? Cancer. 2008 Sep 1;113(5):893-6. Geller JI, Argani P, Adeniran A, Hampton E, De Marzo A, Hicks J, Collins MH. Translocation renal cell carcinoma: lack of negative impact due to lymph node spread. Cancer. 2008 Apr 1;112(7):1607-16. Geller JI, Dome JS. Adjuvant therapy in pediatric patients with completely resected renal cell carcinoma. Pediatr Blood Cancer. 2006 Apr;46(4):527. Geller JI, Dome JS. Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma. Cancer. 2004 Oct 1;101(7):1575-83.
Rajaram Nagarajan, MD, MS Associate Director, Oncology Clinical Operations
Associate Director, Oncology Clinical Operations
Bone tumors; late effects of pediatric cancer therapy
Outcomes following cancer therapy and bone sarcomas
BA: Pre-Medical Sciences, Lehigh University, Bethlehem, PA, 1991.MD: Medical College of Pennsylvania, Philadelphia, PA, 1995.Internship and Residency: Pediatrics, Medical College of Virginia, Richmond, VA, 1998.Fellowship Training: Hematology / Oncology / BMT, University of Minnesota, Minneapolis, MN, 2002.MS: Clinical Research, University of Minnesota, Minneapolis, MN, 2002.
Certifications: Pediatrics, Pediatric Hematology / Oncology.
Nagarajan R, Kamruzzaman A, Ness KK, Marchese VG, Sklar C, Mertens A, Yasui Y, Robison LL, Marina N. Twenty years of follow-up of survivors of childhood osteosarcoma: a report from the childhood cancer survivor study. Cancer. 2011 Feb 1;117(3):625-34.
Rayburg M, Towbin A, Yin H, Maugans T, Maurer B, Nagarajan R, Weiss B. Langerhans cell histiocytosis in a patient with stage 4 neuroblastoma receiving oral fenretinide. Pediatr Blood Cancer. 2009 Dec;53(6):1111-3.
Nagarajan R. Quality of life (QOL) in patients with osteosarcoma. Recent Results Cancer Res. 2009;179:339-44.
Nagarajan R, Mogil R, Neglia JP, Robison LL, Ness KK. Self-reported global function among adult survivors of childhood lower-extremity bone tumors: a report from the Childhood Cancer Survivor Study (CCSS). J Cancer Surviv. 2009 Mar;3(1):59-65. Zebrack BJ, Zevon MA, Turk N, Nagarajan R, Whitton J, Robison LL, Zeltzer LK. Psychological distress in long-term survivors of solid tumors diagnosed in childhood: a report from the childhood cancer survivor study. Pediatr Blood Cancer. 2007 Jul;49(1):47-51.
Khan K, Schwarzenberg SJ, Sharp H, Jessurun J, Gulbahce HE, Defor T, Nagarajan R. Diagnostic endoscopy in children after hematopoietic stem cell transplantation. Gastrointest Endosc. Sep 2006;64(3):379-85.
Schultz KA, Ness KK, Nagarajan R, Steiner ME. Adnexal masses in infancy and childhood. Clinical Obstetrics and Gynecology. Sep 2006; 49(3):464-79. Nagarajan R, Clohisy D, Weigel B. New paradigms for therapy for osteosarcoma. Curr Oncol Rep. 2005 Nov;7(6):410-4.Nagarajan R, Robison LL. Pregnancy outcomes in survivors of childhood cancer. J Natl Cancer Inst Monogr. 2005;(34):72-6.
Spector LG, Ross JA, Nagarajan R. Epidemiology of bone and soft tissue sarcomas. In Pappo A (Ed.) Pediatric Bone and Soft Tissue Tumors. 1st ed. Berlin: Springer-Verlag, 2006.
Brian D. Weiss, MD Associate Director for Safety and Compliance, Cancer and Blood Diseases Institute
Associate Director for Safety and Compliance, Cancer and Blood Diseases Institute
Cincinnati Children's Principal Investigator, New Approaches to Neuroblastoma Therapy Consortium
Medical Director, Neuroblastoma Program
MD: Northwestern University Medical School, Chicago, IL, 1993.
Residency and Chief Residency: Pediatrics, University of California, San Francisco, CA, 1993-1997.
Fellowship: Pediatric Hematology/Oncology, University of California, San Francisco, CA, 1997-2000.
Certification: National Medical Board; Pediatrics;1996, 2002; Pediatric Hematology-Oncology, 2000, 2007
Hummel T, Anyane-Yeboa A, Mo J, Towbin A, Weiss B. Response of NF1-related plexiform neurofibroma to High-Dose Carboplatin. Pediatr Blood Cancer. 2011 Mar;56(3):488-90. Rayburg M, Towbin A, Yin H, Maugans T, Maurer B, Nagarajan R, Weiss B. Langerhans cell histiocytosis in a patient with stage 4 neuroblastoma receiving oral fenretinide. Pediatr Blood Cancer. 2009 Dec;53(6):1111-3. Weiss B, Geiger H, Davies SM. Possible leukemogenic potential of temozolomide. Pediatr Blood Cancer. 2009 Apr;52(4):553.
Chan RJ, Cooper T, Kratz CP, Weiss B, Loh ML. Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium. Leuk Res. 2009 Mar;33(3):355-62.
Wagner LM, McLendon RE, Yoon KJ, Weiss BD, Billups CA, Danks MK. Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5418-25.
Geiger H, Schleimer D, Nattamai KJ, Dannenmann SR, Davies SM, Weiss BD. Mutagenic potential of temozolomide in bone marrow cells in vivo. Blood. 2006 Apr 1;107(7):3010-1.
Weiss B and Shannon K. Preliminary Examples of Preclinical Trials. In Mouse Models of Cancer, Eric Holland (Ed). Wiley-Liss, 2004.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2013 Cincinnati Children's Hospital Medical Center